Results achieved in prior matters are not meant to be a guarantee of success as the facts and legal circumstances vary from matter to matter.
On April 1, 2020, the U.S. Food and Drug Administration (FDA) requested that all prescription and over-the-counter ranitidine (brand name Zantac) products be withdrawn from the market immediately. Zantac belongs to a class of drugs called H2 blockers. Zantac was used to prevent and treat heartburn, acid reflux and other symptoms caused by excess acid produced in the stomach.
The FDA’s request for an immediate recall resulted from findings that certain ranitidine products contained N-Nitrosodimethylamine (NDMA). NDMA has been classified as a probable human carcinogen. Testing has determined that under certain circumstances, NDMA levels in ranitidine products increase under normal storage conditions. Research has shown NDMA levels increase significantly when stored at higher temperatures and over time.
NDMA has been linked with certain cancers including:
If you or a loved one took a prescription or over-the-counter ranitidine product (Zantac) continuously for one month or more and have developed cancer, you may be entitled to compensation. For a free case review, call Wilentz, Goldman & Spitzer, P.A. to speak directly to an attorney about your legal options.
Angelo J. Cifaldi
President and Managing Director; Co-Chair, Mass Tort/Class Action and Cannabis Law Teams
Shareholder
732.855.6096
212.267.3091
Lynne M. Kizis
Co-Chair, Mass Tort/Class Action Team
Shareholder
732.855.6424
212.267.3091
